Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model Corrigendum in /10.3892/ol.2023.13986

Liu,Xiaoyi; Hu,Jianxia; Li,Yueyun; Cao,Weihong; Wang,Yu; Ma,Zhongliang; Li,Funian

doi:10.3892/ol.2018.8166

Mesenchymal stem cells expressing interleukin-18 inhibit breast cancer in a mouse model

Corrigendum in: /10.3892/ol.2023.13986

Authors:
- Xiaoyi Liu
- Jianxia Hu
- Yueyun Li
- Weihong Cao
- Yu Wang
- Zhongliang Ma
- Funian Li
View Affiliations

Affiliations: Breast Disease Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Stem Cell Research Center, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China
Published online on: March 2, 2018 https://doi.org/10.3892/ol.2018.8166
Pages: 6265-6274
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Development of an improved breast cancer therapy has been an elusive goal of cancer gene therapy for a long period of time. Human mesenchymal stem cells derived from umbilical cord (hUMSCs) genetically modified with the interleukin (IL)‑18 gene (hUMSCs/IL‑18) were previously demonstrated to be able to suppress the proliferation, migration and invasion of breast cancer cells in vitro. In the present study, the effect of hUMSCs/IL‑18 on breast cancer in a mouse model was investigated. A total of 128 mice were divided into 2 studies (the early‑effect study and the late‑effect study), with 4 groups in each, including the PBS‑, hUMSC‑, hUMSC/vector‑ and hUMSC/IL‑18‑treated groups. All treatments were injected along with 200 µl PBS. Following therapy, the tumor size, histological examination, and expression of lymphocytes, Ki‑67, cluster of differentiation 31 and cytokines [interleukin (IL)‑18, IL‑12, interferon (IFN)‑γ and TNF‑α] in each group were analyzed. Proliferation of cells (assessed by measuring tumor size and Ki‑67 expression) and metastasis, (by determining pulmonary and hepatic metastasis) of breast cancer cells in the hUMSC/IL‑18 group were significantly decreased compared with all other groups. hUMSCs/IL‑18 suppressed tumor cell proliferation by activating immunocytes and immune cytokines, decreasing the proliferation index of proliferation marker protein Ki‑67 of tumor cells and inhibiting tumor angiogenesis. Furthermore, hUMSCs/IL‑18 were able to induce a more marked and improved therapeutic effect in the tumor sites, particularly in early tumors. The results of the present study indicate that hUMSCs/IL‑18 were able to inhibit the proliferation and metastasis of breast cancer cells in vivo, possibly leading to an approach for a novel antitumor therapy in breast cancer.

View Figures

View References

1	Schrijver WAME, Schuurman K and van Rossum A: Dutch Distant Breast Cancer Metastases Consortium, Peeters T, Ter Hoeve N, Zwart W, van Diest PJ and Moelans CB: Loss of steroid hormone receptors is common in malignant pleural and peritoneal effusions of breast cancer patients treated with endocrine therapy. Oncotarget. 8:55550–55561. 2017. View Article : Google Scholar : PubMed/NCBI
2	Zeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, et al: Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLoS One. 12:e01847472017. View Article : Google Scholar : PubMed/NCBI
3	Ahn JO, Lee HW, Seo KW, Kang SK, Ra JC and Youn HY: Anti-tumor effect of adipose tissue derived-mesenchymal stem cells expressing interferon-β and treatment with cisplatin in a xenograft mouse model for canine melanoma. PLoS One. 8:e748972013. View Article : Google Scholar : PubMed/NCBI
4	Ryu H, Oh JE, Rhee KJ, Baik SK, Kim J, Kang SJ, Sohn JH, Choi E, Shin HC, Kim YM, et al: Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-β and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett. 352:220–227. 2014. View Article : Google Scholar : PubMed/NCBI
5	Lee DH, Ahn Y, Kim SU, Wang KC, Cho BK, Phi JH, Park IH, Black PM, Carroll RS, Lee J and Kim SK: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res. 15:4925–4934. 2009. View Article : Google Scholar : PubMed/NCBI
6	Knoop K, Schwenk N, Dolp P, Willhauck MJ, Zischek C, Zach C, Hacker M, Göke B, Wagner E, Nelson PJ and Spitzweg C: Stromal targeting of sodium iodide symporter using mesenchymal stem cells allows enhanced imaging and therapy of hepatocellular carcinoma. Hum Gene Ther. 24:306–316. 2013. View Article : Google Scholar : PubMed/NCBI
7	Payne NL, Sun G, McDonald C, Layton D, Moussa L, Emerson-Webber A, Veron N, Siatskas C, Herszfeld D, Price J and Bernard CC: Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant. 22:1409–1425. 2013. View Article : Google Scholar : PubMed/NCBI
8	Molloy AP, Martin FT, Dwyer RM, Griffin TP, Murphy M, Barry FP, O'Brien T and Kerin MJ: Mesenchymal stem cell secretion of chemokines during differentiation into osteoblasts, and their potential role in mediating interactions with breast cancer cells. Int J Cancer. 124:326–332. 2009. View Article : Google Scholar : PubMed/NCBI
9	Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T and Kerin MJ: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res. 13:5020–5027. 2007. View Article : Google Scholar : PubMed/NCBI
10	Macho-Fernandez E, Cruz LJ, Ghinnagow R, Fontaine J, Bialecki E, Frisch B, Trottein F and Faveeuw C: Targeted delivery of α-galactosylceramide to CD8α+ dendritic cells optimizes type I NKT cell-based antitumor responses. J Immunol. 193:961–969. 2014. View Article : Google Scholar : PubMed/NCBI
11	Keyhani A, Riazi-Rad F, Pakzad SR and Ajdary S: Human polymorphonuclear leukocytes produce cytokines in response to Leishmania major promastigotes. APMIS. 122:891–897. 2014. View Article : Google Scholar : PubMed/NCBI
12	Sun H, Sun C and Xiao W: Expression regulation of co-inhibitory molecules on human natural killer cells in response to cytokine stimulations. Cytokine. 65:33–41. 2014. View Article : Google Scholar : PubMed/NCBI
13	Lim HX, Hong HJ, Cho D and Kim TS: IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells. J Immunol. 193:5453–5460. 2014. View Article : Google Scholar : PubMed/NCBI
14	Jarry A, Malard F, Bou-Hanna C, Meurette G, Mohty M, Mosnier JF, Laboisse CL and Bossard C: Interferon-alpha promotes Th1 response and epithelial apoptosis via inflammasome activation in human intestinal mucosa. Cell Mol Gastroenterol Hepatol. 3:72–81. 2016. View Article : Google Scholar : PubMed/NCBI
15	Serti E, Werner JM, Chattergoon M, Cox AL, Lohmann V and Rehermann B: Monocytes activate natural killer cells via inflammasome-induced interleukin 18 in response to hepatitis C virus replication. Gastroenterology. 147:209–220.e3. 2014. View Article : Google Scholar : PubMed/NCBI
16	Nakata A, Tsujimura T, Sugihara A, Okamura H, Iwasaki T, Shinkai K, Iwata N, Kakishita E, Akedo H and Terada N: Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells. Anticancer Res. 19:4131–4138. 1999.PubMed/NCBI
17	Coskun U, Gunel N, Sancak B, Onuk E, Bayram M and Cihan A: Effect of tamoxifen on serum IL-18, vascular endothelial growth factor and nitric oxide activities in breast carcinoma patients. Clin Exp Immunol. 137:546–551. 2004. View Article : Google Scholar : PubMed/NCBI
18	Ye ZB, Ma T, Li H, Jin XL and Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol. 13:1747–1751. 2007. View Article : Google Scholar : PubMed/NCBI
19	Liu X, Hu J, Sun S, Li F, Cao W, Wang YU, Ma Z and Yu Z: Mesenchymal stem cells expressing interleukin-18 suppress breast cancer cells in vitro. Exp Ther Med. 9:1192–1200. 2015. View Article : Google Scholar : PubMed/NCBI
20	Doucette T, Rao G, Yang Y, Gumin J, Shinojima N, Bekele BN, Qiao W, Zhang W and Lang FF: Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a glioma model. Neoplasia. 13:716–725. 2011. View Article : Google Scholar : PubMed/NCBI
21	Sage EK, Kolluri KK, McNulty K, Lourenco Sda S, Kalber TL, Ordidge KL, Davies D, Lee Gary YC, Giangreco A and Janes SM: Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax. 69:638–647. 2014. View Article : Google Scholar : PubMed/NCBI
22	Esposito M and Kang Y: Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther. 141:222–233. 2014. View Article : Google Scholar : PubMed/NCBI
23	Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ and Warnock GL: TRAIL-engineered pancreas-derived mesenchymal stem cells: Characterization and cytotoxic effects on pancreatic cancer cells. Cancer Gene Ther. 19:652–658. 2012. View Article : Google Scholar : PubMed/NCBI
24	Müller J, Feige K, Wunderlin P, Hödl A, Meli ML, Seltenhammer M, Grest P, Nicolson L, Schelling C and Heinzerling LM: Double-blind placebo-controlled study with interleukin-18 and interleukin-12-encoding plasmid DNA shows antitumor effect in metastatic melanoma in gray horses. J Immunother. 34:58–64. 2011. View Article : Google Scholar : PubMed/NCBI
25	Choi IK, Lee JS, Zhang SN, Park J, Sonn CH, Lee KM and Yun CO: Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18Rα. Gene Ther. 18:898–909. 2011. View Article : Google Scholar : PubMed/NCBI
26	Yang J, Jin G, Liu X and Liu S: Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice. Hum Gene Ther. 18:323–332. 2007. View Article : Google Scholar : PubMed/NCBI
27	Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
28	Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al: Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8t/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 102:18538–18543. 2005. View Article : Google Scholar : PubMed/NCBI
29	Rodrigues DR, Fernandes RK, Balderramas Hde A, Penitenti M, Bachiega TF, Calvi SA, Dias-Melicio LA, Ikoma MR and Soares ÂM: Interferon-gamma production by human neutrophils upon stimulation by IL-12, IL-15 and IL-18 and challenge with Paracoccidioides brasiliensis. Cytokine. 69:102–109. 2014. View Article : Google Scholar : PubMed/NCBI
30	Ruiz C, Pérez E, García-Martínez O, Díaz-Rodríguez L, Arroyo-Morales M and Reyes-Botella C: Expression of cytokines IL-4, IL-12, IL-15, IL-18, and IFNgamma and modulation by different growth factors in cultured human osteoblast-like cells. J Bone Miner Metab. 25:286–292. 2007. View Article : Google Scholar : PubMed/NCBI
31	Mailliard RB, Alber SM, Shen H, Watkins SC, Kirkwood JM, Herberman RB and Kalinski P: IL-18-induced CD83+ CCR7+ NK helper cells. J Exp Med. 202:941–953. 2005. View Article : Google Scholar : PubMed/NCBI
32	Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ and Kalinski P: Dendritic cells mediate NK cell help for Th1 and CTL responses: Two-signal requirement for the induction of NK cell helper function. J Immunol. 171:2366–2373. 2003. View Article : Google Scholar : PubMed/NCBI
33	Wong JL, Muthuswamy R, Bartlett DL and Kalinski P: IL-18-based combinatorial adjuvants promote the intranodal production of CCL19 by NK cells and dendritic cells of cancer patients. Oncoimmunology. 2:e262452013. View Article : Google Scholar : PubMed/NCBI
34	Zhong L, Roybal J, Chaerkady R, Zhang W, Choi K, Alvarez CA, Tran H, Creighton CJ, Yan S, Strieter RM, et al: Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. Cancer Res. 68:7237–7245. 2008. View Article : Google Scholar : PubMed/NCBI
35	Ribatti D, Belloni AS, Nico B, Di Comite M, Crivellato E and Vacca A: Leptin-leptin receptor are involved in angiogenesis in human hepatocellular carcinoma. Peptides. 29:1596–1602. 2008. View Article : Google Scholar : PubMed/NCBI
36	Gray-Schopfer V, Wellbrock C and Marais R: Melanoma biology and new targeted therapy. Nature. 445:851–857. 2007. View Article : Google Scholar : PubMed/NCBI
37	Yamada N, Hata M, Ohyama H, Yamanegi K, Kogoe N, Nakasho K, Futani H, Okamura H and Terada N: Immunotherapy with interleukin-18 in combination with preoperative chemotherapy with ifosfamide effectively inhibits postoperative progression of pulmonary metastases in a mouse osteosarcoma model. Tumour Biol. 30:176–184. 2009. View Article : Google Scholar : PubMed/NCBI
38	Pappa CA, Alexandrakis MG, Boula A, Psarakis FE, Kolovou A, Bantouna V, Stavroulaki E and Tsirakis G: Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients. Hematol Oncol. 31:201–205. 2013. View Article : Google Scholar : PubMed/NCBI
39	Dwivedi S, Goel A, Natu SM, Mandhani A, Khattri S and Pant KK: Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: A prospective study. Asian Pac J Cancer Prev. 12:1843–1848. 2011.PubMed/NCBI
40	Goto N, Tsurumi H, Kasahara S, Kanemura N, Hara T, Yasuda I, Shimizu M, Murakami N, Sawada M, Yamada T, et al: Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens. Eur J Haematol. 87:217–227. 2011. View Article : Google Scholar : PubMed/NCBI
41	Vidal-Vanaclocha F, Mendoza L, Telleria N, Salado C, Valcárcel M, Gallot N, Carrascal T, Egilegor E, Beaskoetxea J and Dinarello CA: Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 25:417–434. 2006. View Article : Google Scholar : PubMed/NCBI
42	Terme M, Ullrich E, Aymeric L, Meinhardt K, Desbois M, Delahaye N, Viaud S, Ryffel B, Yagita H, Kaplanski G, et al: IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71:5393–5399. 2011. View Article : Google Scholar : PubMed/NCBI
43	Terme M, Ullrich E, Aymeric L, Meinhardt K, Coudert JD, Desbois M, Ghiringhelli F, Viaud S, Ryffel B, Yagita H, et al: Cancer-induced immunosuppression: IL-18-elicited immunoablative NK cells. Cancer Res. 72:2757–2767. 2012. View Article : Google Scholar : PubMed/NCBI